Melbourne, June 24, 2009 (ABN Newswire) - Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful results from the first five patients who underwent bone marrow transplantation with haematopoietic stem and progenitor cells expanded by the patented allogeneic, or “off-the-shelf”, Mesenchymal Precursor Cells (MPCs).
